Pharmacogenetic Analysis of the MIR146A rs2910164 and MIR155 rs767649 Polymorphisms and Response to Anti-TNF Treatment in Patients with Crohn's Disease and Psoriasis
The clinical heterogeneity regarding the response profile of the antitumor necrosis factor (anti-TNF) in patients with Crohn's disease (CD) and psoriasis (PsO) is attributed, amongst others, to genetic factors that influence the regulatory mechanisms which orchestrate the inflammatory response. Here, we investigated the possible associations between the MIR146A rs2910164 and MIR155 rs767649 variants and the response to anti-TNF therapy in a Greek cohort of 103 CD and 100 PsO patients. We genotyped 103 CD patients and 100 PsO patients via the PCR-RFLP method, utilizing the de novo formation of a restriction site for the SacI enzyme considering the MIR146A rs2910164, while Tsp45I was employed for the MIR155 rs767649 variant. Additionally, we investigated the potential functional role of the rs767649 variant, exploring in silico the alteration of transcription factor binding sites (TFBSs) mapped on its genomic location. Our single-SNP analysis displayed a significant association between the rare rs767649 A allele and response to therapy (Bonferroni-corrected p value = 0.012) in patients with PsO, a result further enhanced by the alteration in the IRF2 TFBS caused by the above allele. Our results highlight the protective role of the rare rs767649 A allele in the clinical remission of PsO, implying its utilization as a pharmacogenetic biomarker.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Genes - 14(2023), 2 vom: 09. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nani, Paraskevi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-TNF |
|---|
| Anmerkungen: |
Date Completed 28.02.2023 Date Revised 17.11.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/genes14020445 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353395080 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353395080 | ||
| 003 | DE-627 | ||
| 005 | 20231226210024.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/genes14020445 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1177.xml |
| 035 | |a (DE-627)NLM353395080 | ||
| 035 | |a (NLM)36833372 | ||
| 035 | |a (PII)445 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nani, Paraskevi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacogenetic Analysis of the MIR146A rs2910164 and MIR155 rs767649 Polymorphisms and Response to Anti-TNF Treatment in Patients with Crohn's Disease and Psoriasis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.02.2023 | ||
| 500 | |a Date Revised 17.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The clinical heterogeneity regarding the response profile of the antitumor necrosis factor (anti-TNF) in patients with Crohn's disease (CD) and psoriasis (PsO) is attributed, amongst others, to genetic factors that influence the regulatory mechanisms which orchestrate the inflammatory response. Here, we investigated the possible associations between the MIR146A rs2910164 and MIR155 rs767649 variants and the response to anti-TNF therapy in a Greek cohort of 103 CD and 100 PsO patients. We genotyped 103 CD patients and 100 PsO patients via the PCR-RFLP method, utilizing the de novo formation of a restriction site for the SacI enzyme considering the MIR146A rs2910164, while Tsp45I was employed for the MIR155 rs767649 variant. Additionally, we investigated the potential functional role of the rs767649 variant, exploring in silico the alteration of transcription factor binding sites (TFBSs) mapped on its genomic location. Our single-SNP analysis displayed a significant association between the rare rs767649 A allele and response to therapy (Bonferroni-corrected p value = 0.012) in patients with PsO, a result further enhanced by the alteration in the IRF2 TFBS caused by the above allele. Our results highlight the protective role of the rare rs767649 A allele in the clinical remission of PsO, implying its utilization as a pharmacogenetic biomarker | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Crohn’s disease | |
| 650 | 4 | |a anti-TNF | |
| 650 | 4 | |a miRNA | |
| 650 | 4 | |a pharmacogenetics | |
| 650 | 4 | |a psoriasis | |
| 650 | 4 | |a response to therapy | |
| 650 | 7 | |a Tumor Necrosis Factor Inhibitors |2 NLM | |
| 650 | 7 | |a MIRN155 microRNA, human |2 NLM | |
| 650 | 7 | |a MicroRNAs |2 NLM | |
| 700 | 1 | |a Ladopoulou, Melpomeni |e verfasserin |4 aut | |
| 700 | 1 | |a Papaioannou, Evgenia H |e verfasserin |4 aut | |
| 700 | 1 | |a Papagianni, Evangelia D |e verfasserin |4 aut | |
| 700 | 1 | |a Antonatos, Charalabos |e verfasserin |4 aut | |
| 700 | 1 | |a Xiropotamos, Panagiotis |e verfasserin |4 aut | |
| 700 | 1 | |a Kapsoritakis, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Potamianos, Petros S |e verfasserin |4 aut | |
| 700 | 1 | |a Karmiris, Konstantinos |e verfasserin |4 aut | |
| 700 | 1 | |a Tzathas, Charalambos |e verfasserin |4 aut | |
| 700 | 1 | |a Patsatsi, Aikaterini |e verfasserin |4 aut | |
| 700 | 1 | |a Lazaridou, Elisavet |e verfasserin |4 aut | |
| 700 | 1 | |a Zafiriou, Efterpi |e verfasserin |4 aut | |
| 700 | 1 | |a Roussaki-Schulze, Angeliki |e verfasserin |4 aut | |
| 700 | 1 | |a Georgiou, Sophia |e verfasserin |4 aut | |
| 700 | 1 | |a Grafanaki, Katerina |e verfasserin |4 aut | |
| 700 | 1 | |a Georgakilas, Georgios K |e verfasserin |4 aut | |
| 700 | 1 | |a Vasilopoulos, Yiannis |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Genes |d 2011 |g 14(2023), 2 vom: 09. Feb. |w (DE-627)NLM220446326 |x 2073-4425 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2023 |g number:2 |g day:09 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/genes14020445 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2023 |e 2 |b 09 |c 02 | ||